Immunovant, Inc. Form 10-Q Summary
Reporting period: Three months ended June 30, 2023, the company’s fiscal first quarter of 2024. The filing was signed August 10, 2023. Although the request identifies the period as “2023 Q1,” the filing itself reports the quarter ended June 30, 2023.
Business Context
Immunovant is a clinical-stage biopharmaceutical company developing batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) for autoimmune diseases. The company has no approved products and has never generated product revenue. Batoclimab is being studied in myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy and Graves’ disease. IMVT-1402 entered Phase 1 development during the quarter.
Financial Performance and Liquidity
| Metric | Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $50.6 million | $28.4 million | +$22.1 million |
| Acquired in-process R&D | $12.5 million | $0 | +$12.5 million |
| General and administrative expense | $15.4 million | $11.9 million | +$3.5 million |
| Total operating expenses | $78.5 million | $40.4 million | +$38.1 million |
| Net loss | $73.9 million | $40.4 million | -$33.6 million |
| Net loss per share | $0.57 | $0.35 | Loss increased |
| Net cash used in operating activities | $47.4 million | $65.8 million | +$18.4 million cash benefit |
Interest income was $4.1 million in the quarter, reflecting the company’s cash holdings. Stock-based compensation was $10.7 million, compared with $7.7 million in the prior-year quarter. The company reported no debt outstanding in the balance-sheet information provided.
- Cash and cash equivalents were $330.0 million at June 30, 2023, down from $376.5 million at March 31, 2023.
- Accumulated deficit was $640.3 million; total stockholders’ equity was $299.9 million.
- Current liabilities were $51.4 million, including $26.5 million of accounts payable.
- Cash declined by $46.6 million during the quarter, including $47.4 million used in operations, $0.05 million used for property and equipment and $0.9 million from stock-option exercises.
- Management stated that cash at June 30, 2023 was expected to fund operating expenses and capital expenditures for at least the next 12 months and, under the current operating plan, into the second half of calendar year 2025.
Material Changes Versus the Prior Comparable Period
- Research and development expense increased 78%, primarily due to higher spending on IMVT-1402, batoclimab clinical programs, manufacturing and personnel.
- IMVT-1402 research and development expense increased to $11.5 million from $0.2 million as the company advanced preclinical work, manufacturing and the Phase 1 trial.
- Batoclimab program-specific expense increased to $17.5 million from $10.1 million, driven by endocrine and neurology programs.
- Acquired in-process R&D expense of $12.5 million resulted from the achievement of the third and fourth development and regulatory milestones under the HanAll Agreement.
- General and administrative expense increased primarily because of higher personnel, legal, professional, information technology and market research costs.
- Operating cash use decreased year over year because of favorable working-capital timing, including higher accounts payable and lower prepaid expenses, despite the larger net loss.
- Shares outstanding increased to 130.6 million at June 30, 2023 from 130.3 million at March 31, 2023; additional equity dilution may result from outstanding options and restricted stock units.
Clinical Outlook, Commitments and Risks
- The FDA cleared the IMVT-1402 IND, and the company initiated a Phase 1 healthy-volunteer trial in New Zealand. Initial single-ascending-dose data were expected in September 2023 and multiple-ascending-dose data in October or November 2023.
- A Phase 2 proof-of-concept trial of batoclimab in Graves’ disease began in Germany, with initial results expected in the fourth quarter of calendar 2023.
- Initial data from the CIDP Phase 2b trial were expected in the first half of calendar 2024; myasthenia gravis Phase 3 top-line data were expected in the second half of calendar 2024; and thyroid eye disease Phase 3 top-line results were expected in the first half of calendar 2025.
- The HanAll Agreement includes up to $420.0 million of additional milestone payments after $32.5 million of milestones achieved as of June 30, 2023, plus tiered royalties ranging from the mid-single digits to mid-teens on net sales. The $12.5 million milestone payment was expected to be paid in the quarter ending September 30, 2023.
- The remaining minimum purchase commitment to Samsung for batoclimab manufacturing was approximately $26.5 million, including approximately $13.3 million expected during the remainder of fiscal 2024.
- The company has no committed external source of funding and expects to require additional capital to complete development and potential commercialization. Financing may involve dilution, restrictive debt covenants or the loss of commercial rights.
- Key development risks include uncertain clinical efficacy and safety, patient enrollment and retention, regulatory approval, manufacturing and supply-chain execution, reliance on CROs and third-party manufacturers, competition from other FcRn therapies and the previously observed elevations in cholesterol and LDL associated with batoclimab.
- A putative securities class action remains pending regarding alleged misstatements about batoclimab safety. The company has not recorded a liability because a potential loss could not reasonably be estimated and an unfavorable outcome was not determined to be probable.
- Roivant Sciences Ltd. beneficially owned approximately 56.5% of voting power as of August 4, 2023, giving it substantial control over shareholder matters and creating potential conflicts with minority stockholders.
Most Important Facts for Investors to Verify
- Whether clinical results for batoclimab and IMVT-1402 meet efficacy and safety expectations, particularly regarding lipid and albumin effects.
- Whether the stated cash runway through the second half of calendar 2025 remains valid after clinical, manufacturing and milestone-payment spending.
- The timing and amount of future HanAll milestones, the $12.5 million payment due after quarter-end and any resulting financing needs.
- Progress, enrollment and data timing for the MG, TED, CIDP, Graves’ disease and IMVT-1402 trials.
- Whether additional equity, debt, partnership or licensing financing is required and the resulting dilution or loss of economic rights.
- The status and potential exposure of the securities class action and other litigation.
- Manufacturing capacity, quality and supply commitments with Samsung and other third parties.